奈达铂注射液联合紫杉醇注射液同步放化疗治疗晚期鼻咽癌的临床研究  

Clinical trial of nedaplatin and paclitaxel in combination with concurrent radiotherapy in patients with advanced nasopharyngeal carcinoma

作　　者：谭君武[1] 方呈祥[2] 孙书菊[3] 於席芳 

机构地区：[1]湖北民族学院附属民大医院耳鼻咽喉头颈外科,湖北恩施445000 [2]湖北民族学院附属民大医院肿瘤中心,湖北恩施445000 [3]湖北民族学院附属民大医院超声影像科,湖北恩施445000 [4]黄石市第一医院管理科,湖北黄石435001

出　　处：《中国临床药理学杂志》2016年第22期2114-2116,共3页The Chinese Journal of Clinical Pharmacology

基　　金：湖北省卫生厅科研一般基金资助项目(JX6B104)

摘　　要：目的观察奈达铂注射液联合紫杉醇注射液同步放化疗治疗晚期鼻咽癌的临床疗效。方法 75例晚期鼻咽癌患者随机分为对照组35例和试验组40例。2组均给予放疗,每次2 Gy,每周5次,5周为1个疗程。在放疗的同时对照组第1天静脉滴注顺铂60 mg·m^(-2),5-氟尿嘧啶600 mg·m^(-2),3周为1个疗程。试验组第1天静脉滴注顺铂60 mg·m^(-2),紫杉醇120 mg·m^(-2),奈达铂60mg·m^(-2),2周为1个疗程,共治疗4个疗程。比较2组患者的临床疗效及药物不良反应发生情况。结果治疗后,试验组总有效率为95.00%(38/40例),对照组为62.86%(22/35例),差异有统计学意义(P<0.05)。试验组疾病控制率为77.50%(31/40例),无远处转移率为75.00%(30/40例),5年生存率为82.50%(33/40例);对照组疾病控制率为54.29%(19/35例),无远处转移率为48.57%(17/35例),5年生存率为60.00%(21/35例),2组差异有统计学意义(P<0.05)。对照组出现白细胞减少2例,胃肠道反应2例,口腔黏膜反应1例,药物不良反应发生率为14.29%(5/35例);试验组出现白细胞减少1例,口腔黏膜反应1例,药物不良反应发生率为5.00%(2/40例),差异有统计学意义(P<0.05)。结论奈达铂与紫杉醇联合同步放化疗治疗晚期鼻咽癌的临床效果理想,安全性高。Objective To observe the clinical effect of nedaplatin and pa- clitaxel combined with concurrent chemotherapy in advanced nasopharyn- geal carcinoma. Methods A total of 75 patients with advanced nasopha- ryngeal carcinoma were randomized divided into treatment group（ n =40） and control group （ n = 35 ）. All patients were treated with radiotherapy, 2 Gy a time, 5 times a week, 5 weeks a course. Control group was trea- ted with cisplatin 60 mg. m-2, fluorouracil （5 - FU） 600 mg. m -2 on first day, 3 weeks a course. Treatment group was treated with cisplatin 60 mg. m-2 , paclitaxel 120 mg.m-2 , nedaplatin 60 mg . m-2 on first day, 2 weeks a course, treated for 4 courses. The clinical efficacy and incidence of adverse drug reactions in two groups were compared. Results The total effective rate in treatment group was 95.00% （38/40 eases）, had significant difference with 62.86% （22/35 eases） in control group （P 〈 0. 05 ）. The disease control rate, without distant metastasis and 5 - year survival rate were 77. 50% （31/40 cases） ,75. 00% （30/40 cases ）, 82. 50% （33/40 cases ）in treatment group, had significantdifference with control group, which were 54. 29% （ 19/35 cases ）, 48. 57% （ 17/35 cases ）, 60. 0% （ 21/35 cases, P 〈 0. 05）. In control group, there were 2 cases of white blood cells decreased, 2 cases of gastrointestinal reaction and 1 case of oral mucosa reaction, the incidence rate of adverse drug reactions was 14. 29% （5/3 cases）. There were 1 case of white blood cells decreased and I case of oral mucosa reaction in treatment group, the incidence rate of adverse drug reactions was 5. 00% （2/40 eases, P 〈 0. 05）. Conclusion Nedaplatin and paclitaxel plus concurrent radiotherapy and chemotherapy has good clinical efficacy in the treatment of advanced nasopharyngeal carcinoma, and also safe.

关 键 词：奈达铂 紫杉醇 放化疗 晚期鼻咽癌 

分 类 号：R979.1[医药卫生—药品]